The U.S. Food and Drug Administration (FDA) regulates a wide variety of innovative health care technologies, many of which are rapidly evolving and can allow for increasingly personalized care. These products include algorithm-based diagnostic programs that can learn and change in unpredictable ways and medical devices customized and manufactured for individual patients using 3D printers. FDA oversight must adapt to keep pace with this changing field and ensure that the benefits of emerging technologies outweigh their potential risks.
Pew worked to ensure that FDA could review the safety and effectiveness of such technological advances without hindering innovations that could benefit patients.
Health care organizations are using artificial intelligence (AI)—which the U.S. Food and Drug Administration defines as “the science and engineering of making intelligent machines”—for a growing range of clinical, administrative, and research purposes. This AI software can, for example, help health care providers diagnose diseases, monitor patients’ health, or assist with rote functions such as scheduling patients.
Medical tools enabled with artificial intelligence (AI) can greatly improve health care by helping with problem-solving, automating tasks, and identifying patterns.
Advances in 3D printing, also called additive manufacturing, are capturing attention in the health care field because of their potential to improve treatment for certain medical conditions.
OUR WORK
SIGN UP FOR WEEKLY UPDATES
Don’t miss our latest facts, findings, and survey results in The Rundown
